Research progress of pan-immune inflammation value in prognosis and effect of tumors

LI Tianyi; REN Yue; SONG Zhenya; JIANG Meinan; LI Mengyang; CHEN Yong; YIN Xudong

doi:10.7619/jcmp.20233348

Journal of Clinical Medicine in Practice > 2024 > 28(5): 139-143. > DOI: 10.7619/jcmp.20233348

LI Tianyi, REN Yue, SONG Zhenya, JIANG Meinan, LI Mengyang, CHEN Yong, YIN Xudong. Research progress of pan-immune inflammation value in prognosis and effect of tumors[J]. Journal of Clinical Medicine in Practice, 2024, 28(5): 139-143. DOI: 10.7619/jcmp.20233348

Citation:

PDF (691 KB)

Research progress of pan-immune inflammation value in prognosis and effect of tumors

Department of Oncology, Affiliated Hospital of Yangzhou University, Yangzhou, Jiangsu, 225000

More Information

Received Date: October 21, 2023
Revised Date: December 25, 2023
Available Online: March 21, 2024

Graphical Abstract

Abstract

Abstract

Pan-immune inflammation value (PIV) is a comprehensive immune inflammatory biomarker based on complete blood cell counts, which has been proven to predict treatment response and survival outcomes for different types of tumors. However, the predictive value of the PIV varies in different strategies for tumor treatment. This paper aims to systematically review the latest progress of PIV in predicting survival outcomes and tumor prognosis for immunotherapy, radiotherapy, targeted therapy, endocrine therapy, surgical treatment and neoadjuvant therapy, and analyze its existing challenges and issues, as well as look forward to its future development direction and application prospects.
- tumors,
- pan-immune inflammation value,
- prediction,
- prognosis,
- efficacy,
- biomarkers

FullText(HTML)

References (46)

References

[1]	BRAY F, LAVERSANNE M, WEIDERPASS E, et al. The ever-increasing importance of cancer as a leading cause of premature death worldwide[J]. Cancer, 2021, 127(16): 3029-3030. doi: 10.1002/cncr.33587
[2]	COLOTTA F, ALLAVENA P, SICA A, et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability[J]. Carcinogenesis, 2009, 30(7): 1073-1081. doi: 10.1093/carcin/bgp127
[3]	KITAMURA T, QIAN B Z, POLLARD J W. Immune cell promotion of metastasis[J]. Nat Rev Immunol, 2015, 15(2): 73-86. doi: 10.1038/nri3789
[4]	DIAKOS C I, CHARLES K A, MCMILLAN D C, et al. Cancer-related inflammation and treatment effectiveness[J]. Lancet Oncol, 2014, 15(11): e493-e503. doi: 10.1016/S1470-2045(14)70263-3
[5]	CRUSZ S M, BALKWILL F R. Inflammation and cancer: advances and new agents[J]. Nat Rev Clin Oncol, 2015, 12(10): 584-596. doi: 10.1038/nrclinonc.2015.105
[6]	MALLA M, LOREE J M, KASI P M, et al. Using circulating tumor DNA in colorectal cancer: current and evolving practices[J]. J Clin Oncol, 2022, 40(24): 2846-2857. doi: 10.1200/JCO.21.02615
[7]	WINTHER-LARSEN A, AGGERHOLM-PEDERSEN N, SANDFELD-PAULSEN B. Inflammation-scores as prognostic markers of overall survival in lung cancer: a register-based study of 6, 210 Danish lung cancer patients[J]. BMC Cancer, 2022, 22(1): 63. doi: 10.1186/s12885-021-09108-5
[8]	HU B, YANG X R, XU Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma[J]. Clin Cancer Res, 2014, 20(23): 6212-6222. doi: 10.1158/1078-0432.CCR-14-0442
[9]	MENG L H, YANG Y J, HU X, et al. Prognostic value of the pretreatment systemic immune-inflammation index in patients with prostate cancer: a systematic review and meta-analysis[J]. J Transl Med, 2023, 21(1): 79. doi: 10.1186/s12967-023-03924-y
[10]	黄嘉宝, 桑玉, 全小庆, 等. 老年消化道肿瘤患者外周血中系统免疫炎症指数的研究进展[J]. 中华老年病研究电子杂志, 2019, 6(4): 35-39. doi: 10.3877/cma.j.issn.2095-8757.2019.04.008
[11]	FUCÀ G, GUARINI V, ANTONIOTTI C, et al. The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials[J]. Br J Cancer, 2020, 123(3): 403-409. doi: 10.1038/s41416-020-0894-7
[12]	GUVEN D C, ERUL E, YILMAZ F, et al. The association between pan-immune-inflammation value and survival in head and neck squamous cell carcinoma[J]. Eur Arch Otorhinolaryngol, 2023, 280(5): 2471-2478. doi: 10.1007/s00405-022-07804-x
[13]	YEH C C, KAO H K, HUANG Y, et al. Discovering the clinical and prognostic role of pan-immune-inflammation values on oral cavity squamous cell carcinoma[J]. Cancers, 2023, 15(1): 322. doi: 10.3390/cancers15010322
[14]	DEMIR H, DEMIRCI A, EREN S K, et al. A new prognostic index in young breast cancer patients[J]. J Coll Physicians Surg Pak, 2022, 32(1): 86-91. doi: 10.29271/jcpsp.2022.01.86
[15]	KARADAG I, KARAKAYA S, YILMAZ M E, et al. The potential prognostic novel markers PIV and PILE score to predict survival outcomes at hepatocellular cancer[J]. Eur Rev Med Pharmacol Sci, 2022, 26(20): 7679-7686.
[16]	刘贤明, 彭丽丽, 任燕燕, 等. HER2阴性晚期胃癌患者外周血LMR、SII与PIV对生存结局的预测价值及预后影响因素研究[J]. 临床误诊误治, 2022, 35(11): 47-53. https://www.cnki.com.cn/Article/CJFDTOTAL-LCWZ202211011.htm
[17]	靳爽, 李坤, 陈泓润, 等. PIV和AAPR对非小细胞肺癌伴脑转移患者的预后评估价值[J]. 癌变·畸变·突变, 2023, 35(1): 43-48. https://www.cnki.com.cn/Article/CJFDTOTAL-ABJB202301008.htm
[18]	GAMBICHLER T, STANG A, MANSOUR R, et al. Prognostic potential of the baseline pan-immune-inflammation value and neutrophil/lymphocyte ratio in stage Ⅰ to Ⅲ melanoma patients[J]. Cancers, 2022, 14(18): 4410. doi: 10.3390/cancers14184410
[19]	徐方, 王红兵, 吕爱红, 等. PIV对晚期胃癌患者PD-1抑制剂治疗的预后价值[J]. 现代消化及介入诊疗, 2023, 28(1): 85-89. https://www.cnki.com.cn/Article/CJFDTOTAL-XDXH202301018.htm
[20]	ZENG R, LIU F, FANG C, et al. PIV and PILE score at baseline predict clinical outcome of anti-PD-1/PD-L1 inhibitor combined with chemotherapy in extensive-stage small cell lung cancer patients[J]. Front Immunol, 2021, 12: 724443. doi: 10.3389/fimmu.2021.724443
[21]	GUVEN D C, YILDIRIM H C, BILGIN E, et al. PILE: a candidate prognostic score in cancer patients treated with immunotherapy[J]. Clin Transl Oncol, 2021, 23(8): 1630-1636. doi: 10.1007/s12094-021-02560-6
[22]	CORTI F, LONARDI S, INTINI R, et al. The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors[J]. Eur J Cancer, 2021, 150: 155-167. doi: 10.1016/j.ejca.2021.03.043
[23]	TOPKAN E, SELEK U, KUCUK A, et al. Low pre-ChemoradiotherapyPan-immune-inflammation value (PIV) measures predict better survival outcomes in locally advanced pancreatic adenocarcinomas[J]. J Inflamm Res, 2022, 15: 5413-5423. doi: 10.2147/JIR.S385328
[24]	CHEN X R, HONG X C, CHEN G, et al. The Pan-Immune-Inflammation Value predicts the survival of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer treated with first-line ALK inhibitor[J]. Transl Oncol, 2022, 17: 101338. doi: 10.1016/j.tranon.2021.101338
[25]	LIGORIO F, FUCÀ G, ZATTARIN E, et al. The pan-immune-inflammation-value predicts the survival of patients with human epidermal growth factor receptor 2(HER2)-positive advanced breast cancer treated with first-line taxane-trastuzumab-pertuzumab[J]. Cancers, 2021, 13(8): 1964. doi: 10.3390/cancers13081964
[26]	YAZGAN S C, YEKEDVZ E, UTKAN G, et al. Prognostic role of pan-immune-inflammation value in patients with metastatic castration-resistant prostate cancer treated with androgen receptor-signaling inhibitors[J]. Prostate, 2022, 82(15): 1456-1461. doi: 10.1002/pros.24419
[27]	宋科, 费素娟, 李博闻, 等. 术前泛免疫炎症值及全身免疫炎症指数在食管鳞癌中的预后价值[J]. 现代消化及介入诊疗, 2022, 27(7): 834-839. https://www.cnki.com.cn/Article/CJFDTOTAL-XDXH202207007.htm
[28]	LIN F, ZHANG L P, XIE S Y, et al. Pan-immune-inflammation value: a new prognostic index in operative breast cancer[J]. Front Oncol, 2022, 12: 830138. doi: 10.3389/fonc.2022.830138
[29]	SATO S, SHIMIZU T, ISHIZUKA M, et al. The preoperative pan-immune-inflammation value is a novel prognostic predictor for with stage Ⅰ~Ⅲ colorectal cancer patients undergoing surgery[J]. Surg Today, 2022, 52(8): 1160-1169. doi: 10.1007/s00595-021-02448-6
[30]	ŞAHIN A B, CUBUKCU E, OCAK B, et al. Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy[J]. Sci Rep, 2021, 11(1): 14662. doi: 10.1038/s41598-021-94184-7
[31]	TRUFFI M, SOTTOTETTI F, GAFNI N, et al. Prognostic potential of immune inflammatory biomarkers in breast cancer patients treated with neoadjuvant chemotherapy[J]. Cancers, 2022, 14(21): 5287. doi: 10.3390/cancers14215287
[32]	WANG S B, CHEN J Y, XU C, et al. Evaluation of systemic inflammatory and nutritional indexes in locally advanced gastric cancer treated with adjuvant chemoradiotherapy after D2 dissection[J]. Front Oncol, 2022, 12: 1040495. doi: 10.3389/fonc.2022.1040495
[33]	TOPKAN E, KUCUK A, SELEK U. Pretreatment pan-immune-inflammation value efficiently predicts survival outcomes in glioblastoma multiforme patients receiving radiotherapy and temozolomide[J]. J Immunol Res, 2022, 2022: 1346094.
[34]	HEDRICK C C, MALANCHI I. Neutrophils in cancer: heterogeneous and multifaceted[J]. Nat Rev Immunol, 2022, 22(3): 173-187. doi: 10.1038/s41577-021-00571-6
[35]	DE VISSER K E, JOYCE J A. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth[J]. Cancer Cell, 2023, 41(3): 374-403. doi: 10.1016/j.ccell.2023.02.016
[36]	JAILLON S, PONZETTA A, DI MITRI D, et al. Neutrophil diversity and plasticity in tumour progression and therapy[J]. Nat Rev Cancer, 2020, 20(9): 485-503. doi: 10.1038/s41568-020-0281-y
[37]	HAEMMERLE M, STONE R L, MENTER D G, et al. The platelet lifeline to cancer: challenges and opportunities[J]. Cancer Cell, 2018, 33(6): 965-983. doi: 10.1016/j.ccell.2018.03.002
[38]	SCHLESINGER M. Role of platelets and platelet receptors in cancer metastasis[J]. J Hematol Oncol, 2018, 11(1): 125. doi: 10.1186/s13045-018-0669-2
[39]	REN J H, HE J Y, ZHANG H J, et al. Platelet TLR4-ERK5 axis facilitates NET-mediated capturing of circulating tumor cells and distant metastasis after surgical stress[J]. Cancer Res, 2021, 81(9): 2373-2385. doi: 10.1158/0008-5472.CAN-20-3222
[40]	OLINGY C E, DINH H Q, HEDRICK C C. Monocyte heterogeneity and functions in cancer[J]. J Leukoc Biol, 2019, 106(2): 309-322. doi: 10.1002/JLB.4RI0818-311R
[41]	JEONG J, SUH Y, JUNG K. Context drives diversification of monocytes and neutrophils in orchestrating the tumor microenvironment[J]. Front Immunol, 2019, 10: 1817. doi: 10.3389/fimmu.2019.01817
[42]	DEVALARAJA S, TO T K J, FOLKERT I W, et al. Tumor-derived retinoic acid regulates intratumoral monocyte differentiation to promote immune suppression[J]. Cell, 2020, 180(6): 1098-1114, e16. doi: 10.1016/j.cell.2020.02.042
[43]	CHRISTOFIDES A, STRAUSS L, YEO A, et al. The complex role of tumor-infiltrating macrophages[J]. Nat Immunol, 2022, 23(8): 1148-1156. doi: 10.1038/s41590-022-01267-2
[44]	CHEW V, CHEN J M, LEE D M, et al. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma[J]. Gut, 2012, 61(3): 427-438. doi: 10.1136/gutjnl-2011-300509
[45]	JIANG D X, LIU Y L, WANG H, et al. Tumour infiltrating lymphocytes correlate with improved survival in patients with esophageal squamous cell carcinoma[J]. Sci Rep, 2017, 7: 44823. doi: 10.1038/srep44823
[46]	GOUGH N R, XIANG X Y, MISHRA L. TGF-β signaling in liver, pancreas, and gastrointestinal diseases and cancer[J]. Gastroenterology, 2021, 161(2): 434-452, e15. doi: 10.1053/j.gastro.2021.04.064

Cited By

Get Citation

PDF

XML

Article views (178) PDF downloads (21)

Turn off MathJax

Article Contents

Abstract

References

Research progress of pan-immune inflammation value in prognosis and effect of tumors

Abstract

References

Catalog

Export File

Citation

Format

Content